Articles dans des revues avec comité de lecture (34)
  1. 25. Najar, M., Krayem, M., Merimi, M., Burny, A., Meuleman, N., Bron, D., Raicevic, G., & Lagneaux, L. (2018). Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts. Inflammation research. doi:10.1007/s00011-018-1131-1
  2. 26. Najar, M., Krayem, M., Meuleman, N., Bron, D., Busser, H., & Lagneaux, L. (2017). Immunohematology Mesenchymal Stromal Cell-based Therapy: From Research to Clinic. Applied immunohistochemistry & molecular morphology : AIMM. doi:10.1097/PAI.0000000000000629
  3. 27. Perdrix, A., Najem, A., Saussez, S., Awada, A., Journé, F., Ghanem, G. E., & Krayem, M. (2017). PRIMA-1 and PRIMA-1Met (APR-246): From mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies. Cancers (Basel), 9(12), 172. doi:10.3390/cancers9120172
  4. 28. Najem, A., Krayem, M., Perdrix, A., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2017). New drug combination strategies in melanoma: Current status and future directions. Anticancer research, 37(11), 5941-5953. doi:10.21873/anticanres.12041
  5. 29. Najem, A., Krayem, M., Sales, F., Hussein, N., Badran, B., Robert, C., Awada, A., Journé, F., & Ghanem, G. E. (2017). P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. European journal of cancer, 83, 154-165. doi:10.1016/j.ejca.2017.06.033
  6. 30. Najar, M., Krayem, M., Meuleman, N., Bron, D., & Lagneaux, L. (2017). Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review. Immune network, 17(2), 89-102. doi:10.4110/in.2017.17.2.89
  7. 31. Vlková, K., Réda, J., Ondruŝová, L., Krayem, M., Ghanem, G. E., & Vachtenheim, J. (2016). GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax. International journal of oncology, 49(3), 953-960. doi:10.3892/ijo.2016.3596
  8. 32. Krayem, M., Journé, F., Wiedig, M., Morandini, R., Najem, A., Sales, F., van Kempen, L., Sibille, C., Awada, A., Marine, J.-C., & Ghanem, G. E. (2016). P53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib. European journal of cancer, 55, 98-110. doi:10.1016/j.ejca.2015.12.002
  9. 33. El Hajj, P., Krayem, M., Fayyad Kazan, H., Badran, B., Ghanem, G. E., & Journé, F. (2015). Differential expression profiles of microRNAs involved in malignant melanocyte pigmentation. International Journal of Biological & Pharmaceutical Research, 6, 411-418.
  10. 34. Krayem, M., Journé, F., Wiedig, M., Morandini, R., Sales, F., Awada, A., & Ghanem, G. E. (2014). Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib. European journal of cancer. doi:10.1016/j.ejca.2014.01.021
    11.   Thèses et mémoires (1)
  11. 1. Krayem, M. (2015). MAPK pathway as a target for therapy in melanoma (Thèse doctorale non-publiée). Université libre de Bruxelles, Faculté de Pharmacie, Bruxelles.
    12. << Précédent 1 2 3 Suivant >>